The Influence of Microenvironment on Survival of Intraportal Transplanted Islets

Ling-ling Yan1,2†, Li-ping Ye1,2,3†, Ya-hong Chen4, Sai-qin He5, Chen-yang Zhang5, Xin-li Mao1,2,3* and Shao-wei Li1,2,3*

OPEN ACCESS

1 Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province, Taizhou Hospital Affiliated to Wenzhou Medical University, Linhai, China, 2 Department of Gastroenterology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China, 3 Institute of Digestive Disease, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China, 4 Health Management Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China, 5 Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China

Clinical islet transplantation has the potential to cure type 1 diabetes. Despite recent therapeutic success, it is still uncommon because transplanted islets are damaged by multiple challenges, including instant blood mediated inflammatory reaction (IBMIR), inflammatory cytokines, hypoxia/reperfusion injury, and immune rejection. The transplantation microenvironment plays a vital role especially in intraportal islet transplantation. The identification and targeting of pathways that function as “master regulators” during deleterious inflammatory events after transplantation, and the induction of immune tolerance, are necessary to improve the survival of transplanted islets. In this article, we attempt to provide an overview of the influence of microenvironment on the survival of transplanted islets, as well as possible therapeutic targets.

Keywords: islet transplantation, microenvironment, instant blood, mediated inflammatory reaction, inflammatory cytokine, therapeutic target

INTRODUCTION

Although type 1 diabetes cannot be prevented or reversed, islet transplantation—which restores insulin independence and prevents severe hypoglycemia—is currently proving to be a promising treatment (1, 2). However, the results of multiple clinical trials have shown that most transplant recipients fail to achieve complete insulin independence. Although the immunosuppressive regimen reported from Edmonton, Canada, has achieved unprecedented success in achieving insulin independence in islet transplantation (3), there are still some problems that affect the outcome of islet transplantation. Advancements in the acquisition of pancreatic islets, immunosuppression of islet recipients, and an increase in the number of transplanted islets are required (4). The average human pancreas has 300,000 to 1.5 million pancreatic islets, and only 60% of this islet cell mass is needed to maintain a normal glucose metabolism (5). However, 72% of islet recipients still require more than two successfully processed islet preparations to obtain a sufficient beta cell mass to compensate for islet death in the post-transplantation period (6). However, the source of pancreatic islets is limited.

It was observed that only 10% of recipients remain insulin dependent for more than 5 years and that most recipients re-use insulin because of a decline in the islet function over time (7). During
transplantation, islet grafts are damaged by multiple challenges, including enzyme and mechanical damage caused by the isolation process, hypoxia, inflammation, immune rejection and toxicity of immunosuppressive drugs (8). The liver is currently the preferred transplantation site because the procedure is minimally invasive, easy to perform, and has low rates of bleeding and thrombosis (9). Early inflammatory responses strongly influence islet engraftment and survival after intrahepatic transplantation. This early immune response is triggered by immediate blood-mediated inflammatory response (IBMIR) and ischemia-reperfusion injury (10). Elevated inflammatory cytokines interleukin-1β (IL-1β), tumor necrosis factor α (TNF-α), interferon-γ (IFN-γ), were observed during islet transplantation, and macrophages also involved in regulating the cell injury of transplanted pancreatic islets (11). It was observed that concomitant transplantation of islets and vascular endothelial cells in diabetic rats can prolong the survival of islet grafts (12). Previous studies have found that cytokine inhibitors or drugs that inhibit the activation of liver macrophage activation can improve the function of pancreatic islets after transplantation (13, 14). Changes in the microenvironment, mainly involving inflammatory cytokines, endothelial cells, and immune cells, play a key role in the survival of islet grafts. This review discusses the changes in the microenvironment (inflammatory cytokines, immune cells, endothelial cells, etc.) during clinical intraportal islet transplantation, and their influence on the survival of the islet grafts, with the aim of improving the success of clinical islet transplantation.

**STATUS AND RECENT PROGRESS OF CLINICAL INTRAPORTAL ISLET TRANSPLANTATION**

In 1990, David Scharp et al. reported the first case of type 1 diabetes allogeneic intraportal islet transplantation resulting in a short-term insulin independence, which opened the prelude to clinical islet transplantation (15). The International Islet Registry collected data from 267 islet allogeneic transplants from multiple centers between 1990 and 2001, only 12.4% of cases achieved insulin independence periods of at least 1 week, and 8.2% maintained insulin independence for more than 1 year. Appropriate immunosuppression remained a critical piece of the unsolved puzzle in order to improve long-term graft function and sustained insulin independence (16). Until 2000, Edmonton’s group reported that insulin independence was achieved in seven patients with type 1 diabetes who underwent islet transplantation. This protocol established the need for sufficient islet β cell mass for transplantation and also proposed a glucocorticoid-free immunosuppressive regimen (3). Since the publication of the Edmonton protocol, many countries around the world have successively carried out allogeneic islet transplantation for the treatment of type 1 diabetes. Extended follow-up of these trials showed a gradual loss of insulin independence over time with renewed need for exogenous insulin, with only 10% of patients showing insulin independence at 5 years after transplantation (7). Hering et al. reported in 2016 that the North American Clinical Islet Transplant Consortium conducted a multicenter, single-arm, phase 3 trial to further evaluate the efficacy of allogeneic islet transplantation. The assay, using product purified human pancreatic islets, achieved an HbA1c of 5.6% in the absence of severe hypoglycemia (17). A subsequent multicenter, open-label, randomized controlled trial in Europe reconfirmed the benefit of islet transplantation over intensive insulin therapy in patients with type 1 diabetes with severe hypoglycemia or after kidney transplantation (18). Recently, Marco et al. proposed that vitamin D alone or in combination with other anti-inflammatory agents may serve as a new immunomodulatory strategy to reduce the recurrence of autoimmune/allogeneic transplant rejection in intraportal islet transplantation, but its safety and efficacy further validation in large prospective studies is required (19). In intraportal islet transplantation model, islet pretreatment with mitomycin C prolonged graft survival by suppressing pro-inflammatory events and inducing latent regulatory lymphocytes (20). Xenogeneic and stem cell-derived islet tissues have entered early clinical trials, although much remains to be learned about the in vivo physiology and immunogenicity of various products. These advances provide more options for cellular therapy in diabetes treatment, providing an unlimited source of pancreatic islet tissue for future applications (21).

**INTRAPORTAL ISLET TRANSPLANTATION CHALLENGES AND STRATEGIES**

Instant blood mediated inflammatory reaction (IBMIR)

The IBMIR, which is triggered by exposed tissue factor on the islet surface and characterized by platelet activation and aggregation, and activation of the coagulation and complement systems, is a major obstacle after islet transplantation. Moreover, it increases the infiltration of neutrophils, monocytes and macrophages (13). These reactions are thought to cause the immediate loss of most of the transplanted islets (22), and may also increase the risk of islet rejection later through adaptive immune responses (23). Potential means for reducing islet inflammation and protecting islets can be achieved by the addition of anti-inflammatory agents, anticoagulants or coating islets with various protective macromolecules during islet culture (24). In vitro and in vivo experiments demonstrated that low molecular weight dextran sulfate prevented IBMIR, leukocyte infiltration was eliminated at high doses, and transplanted pig islets survived significantly longer in recipients treated with low molecular weight dextran sulfate (25). Another phase II, multicenter, active-controlled, randomized study, the Clinical Islet Transplant Consortium 01 study, revealed that systemic low molecular weight dextran sulfate treatment showed similar efficacy to heparin treatment in preventing IBMIR and promoting islet engraftment (26). However, the reason for the current reluctance to use it is that its target-activated partial
thromboplastin time is 3 times longer than heparin’s (27). The use of biotin/avidin technology to bind preformed heparin complexes to the islet surface resulted in protection against IBMIR in vitro loop model and in an allogeneic porcine model of clinical islet transplantation (28). In vitro and in vivo data suggested that activated protein C exerted anti-inflammatory and anti-apoptotic activities by directly acting on cells after exposure of hepatic endothelial cells to pancreatic islets (29). However, the above remain to be verified by clinical studies (30, 31). And it has been confirmed that Cibinetide can reduce IBMIR related platelet consumption in a pro-inflammatory environment and protect isolated human islets (32). The evidence showed that α-1 antitrypsin inhibited IBMIR, which resulted in improved outcome of intraportal islet transplantation in mouse model (33). Currently, the addition of heparin is the standard approach but it is insufficient (27).

**COMPLEMENT SYSTEM**

Complement activation is triggered by natural immunoglobulin (Ig)G or IgM. When isolated islets are exposed to blood, the complement system is rapidly activated and causes lysis of islet cells (34). Complement activation occurs via the classical pathway and an alternative pathway, which leads to the formation of a complex composed of C5b-9, which forms a “channel” through the cell membrane, leading to cell lysis and death. Another major function of the complement system is the production of anaphylatoxins C3a and C5a, which enhance the inflammatory response to islets (23). C3a and C5a produced by complement activation are powerful chemoattractants for macrophages and neutrophils (10). Activation through the C5a receptor can cause granulocytes to release enzymes, such as myeloperoxidase and elastase, and promote monocytes to release cytokines, such as IL-1, IL-6, IL-8, and TNF-a. C5a stimulates endothelial cells to release heparin sulfate, upregulate tissue factor, secrete von Willebrand factor and express P-selectin, which is conducive to thrombin and express P-selectin, which is conducive to thrombin, platelet aggregation and polymorphonuclear leukocyte adhesion (23). Tissue factor and many adhesion molecules can be expressed by endothelial cells triggered by soluble C5b-9 (sC5b-9) (35). Complement activation may therefore induce direct inflammation and indirect effects mediated by endothelial cells.

In allogeneic transplantation, C3 is one of the important factors triggering rejection in mice (36, 37) and humans (38). Numerous studies have shown that the combination of C3 fragment C3dg with an antigen can be used as a strong adjuvant to promote both cellular and humoral responses (39). Therefore, it can be reasonably expected that complement activation and C3dg binding will trigger an immune response, leading to an adaptive immune response to the graft (34). Therefore, small interfering RNA (siRNA) targeting C3 and C5a receptors may increase the viability of transplanted islets (40).

**HYPOXIC DAMAGE**

Islets are easily damaged under hypoxic conditions prior to transplantation (including pancreas procurement, islet isolation and culture) and exposure to hypoxic environment of the transplant site after transplantation (41). Hypoxia damages islet β cell function, which manifested anaerobic glycolysis, showed elevated lactate and reduced responsiveness to high glucose levels (42). The decrease of blood oxygen partial pressure can lead to irreversible β cell dysfunction, resulting in higher fasting blood-glucose and lower C-peptide levels (43). Calcium influx into islet cells has also been shown to cause cell damage in rat and human islets cultured under hypoxic conditions (44). In order to cope with the impact of hypoxia on the quality and function of islets, the following explorations were attempted: (1) Compared with static cold storage, perfusion effectively reduced anoxic death of islet cells, and islet production was higher after perfusion (45, 46). Perfluorohexyloctan, a semi-fluorinated liquid fluorocarbon, maintained higher intrapancreatic pO2 and improved islet viability and function with porcine pancreas (47, 48). In addition, oxygen supply can be increased and oxygenation of islets can be improved by decreasing the culture density of islets before transplantation (46, 49). (2) Photosynthesis of thermostable microalga (Chlorella sorokiniana) was applied as a method to supply oxygen to cultured islets coencapsulating in alginate gel (50). Microparticle-mediated-oxygenation has been studied to improve islet transplantation. Co-transplantation of oxygen-generating microparticles and minimal islet mass within fibrin-conjugated heparin/VEGF collagen scaffold has enormous potential to enhance islet revascularization, diabetes reversal and oxygenation (51). (3) As mentioned above, the influx of calcium ions into islet cells can also induce islet injury. It was found that potassium channel activator (diazoxide) and calcium channel blocker (nifedipine) were helpful to restore the synthesis of insulin protoplasts and islet cell necrosis caused by hypoxia when used as preconditioning agents (44, 52). (4) Curcumin has the ability to protect β cells from hypoxia damage (53). Pueroxin could alleviate β cell apoptosis and malfunction by hypoxic injury of β cells in corpulent mice induced by cobalt chloride induced via PI3K/Akt pathway activation (54). (5) Reconstructing the capillary network in islets is very important to prevent hypoxia and preserve function. Previous studies have shown the effectiveness of prevascularization of the graft bed for subcutaneous islet graft survival (55–58). The use of islet-cell cluster in clinical islet transplantation may be a strategy to prevent islet loss caused by hypoxia after transplantation (59).

**IMMUNOSUPPRESSIVE DRUG TOXICITY AND IMMUNE TOLERANCE INDUCTION**

During intraportal islet transplantation, isolated islets are exposed to high levels of immunosuppressive drugs, which are detrimental to islet engraftment/survival and long-term function (60). Previously, the standard protocol of immunosuppression
for islet transplantation included a combination of corticosteroids, calcineurin inhibitors (tacrolimus and cyclosporine), and purine analogs (mycophenolate mofetil). Many of the above drugs had been shown to be diabetogenic, impairing insulin secretion (61). The Edmonton protocol in 1999 took a major step forward in islet transplantation with the introduction of steroid-free therapy based on low-dose sirolimus, tacrolimus, and daclizumab (3). Although the results of multicenter clinical trials suggested that this protocol could provide short-term insulin independence and reduce the incidence of acute rejection (62), patients receiving long-term immunosuppressive drugs are susceptible to multiple adverse effects, such as infections (63), malignancies (64), de novo diabetes (65) and organ toxicities (66).

Immune tolerance induction is a promising strategy to accept histocompatibility complex (MHC)-mismatched allografts without reducing resistance to infection or increasing other complications (67). For immunological tolerance to allografts, the high proportion of MHC alloreactive T cell is considered as a major barrier to tolerance induction. Central T cell tolerance refers to the deletion of reactive clones in the thymus during negative selection. Peripheral T cell tolerance includes peripheral deletion, anergy/exhaustion, and suppressive function of regulatory T cells (Treg) (68). At present, how to apply the inherent immune tolerance mechanism of the human system to induce donor-specific immune tolerance is the key to solving transplant rejection (69). Singh et al. reported that apoptotic donor lymphocyte infusion prior to transplantation induced long-term tolerance (>1 year) of islet grafts in a non-human primate (NHP) model, which had made a breakthrough in the tolerance induction protocol for allogeneic islet transplantation (70).

Intrathymic inoculation of recipient APCs pulsed with allopeptides can induce intrathymic tolerance, however it is an invasive technique and the thymus regresses with age and has limited potential in adults (71). Another potentially more effective approach to achieving central tolerance is the generation of hematopoietic chimerism or mixed allogeneic chimerism, with lethal total body irradiation or the generation of hematopoietic chimerism or mixed more effective approach to achieving central tolerance is monoclonal antibodies or costulatory blockade) in the prospective transplant recipients, in order to make room for the transplanted bone marrow. Bone marrow cell transplantation can reconstitute the recipient's hematopoietic compartment with donor hematopoietic stem cells, inducing donor-specific tolerance to islet allografts (62, 72). Another strategy to induce tolerance is to deplete alloreactive T cells prior to transplantation, promoting a hyporesponsive environment that drives tolerance transition (73). T cell depletion can be achieved by total body irradiation, lymphocyte depleting alloantibodies. Among them, antithymocyte globulin (ATG) is a potent inducer of T cell depletion, and ATG alone or in combination with other drugs can prolong the survival of allografts (74, 75). Other pathways for inducing immune tolerance include costimulatory signal blockades, induction and expansion of regulatory T (Treg) cells, etc (62). And in the intrahepatic mouse allogeneic islet transplantation model, Lee et al. demonstrated for the first time that short-term single administration of anti-CD154 monoclonal antibody could induce FoxP3+ Treg cell-mediated immune tolerance (67).

KEY INFLAMMATORY FACTORS AND CELLS ASSOCIATED WITH ISLET CELL DYSFUNCTION

Several mediators have been found to cause islet dysfunction and/or cellular death after islet transplantation, including inflammatory cytokines (IL-1β, TNF-α, and IFN-γ), nitric oxide (NO), and nitric oxide synthase (iNOS) (76).

IL-1β

IL-1β is one of the most important mediators of islet injury and plays an important role in the process of pancreatic islets dysfunction, which may represent an early inflammatory marker of graft failure (77). IL-1β is secreted by Kupffer cells, islet resident macrophages, and neutrophils around the transplantation site (78). IL-1β secretion increases during islet acquisition, islet isolation, islet culture, and islet transplantation (77). IL-1β binds to the IL-1β receptor (IL-1βR) on the surface of pancreatic islet cells, causing TNF receptor-related factor 6 (TRAF6) to be activated by IL-1 receptor-related kinase (IRAK), which in turn leads to the phosphorylation and degradation of IκB. Then NF-κB is released from inhibitory IκB, transferred from the cytoplasm to the nucleus, and regulates the transcription of various genes, including IL-1, IL-6, TNF-α, and iNOS (76, 79) (Figure 1). Activation of iNOS results in the production of NO, which is directly related to β-cell apoptosis (80).

The damage of islet cells starts from the donor. Although most pancreatic islet transplants use organs from heart-beating brain-dead (BD) donors, acute physiological changes after brain death of BD donors may still cause significant damage to islets from inflammatory events. Brain death can stimulate various cells to produce pro-inflammatory cytokines, and produce a so-called “cytokine storm”, including IL-1β in BD donors, which greatly reduces the islet yield, functionality, vitality, and engraftment after transplantation (8). One study has shown that the administration of exendin-4 to BD donors can reduce the expression of IL-1β, thereby increasing both the islet viability and insulin secretion in the pancreas after glucose stimulation in a BD rat model (81). In the BD rat model, treatment with a selective neutrophil elastase inhibitor, sivelestat sodium, decreased the expression of IL-1β, significantly improved the islet yield and function in vitro, and suppressed hypercytokinemia-mediated beta-cell death (82).

Then, in the process pancreas digestion and islet purification, enzymatic and mechanical stress can induce inflammatory mediators, such as IL-1β, in the islets (77). The islet basement membrane is lysed during the digestion and separation of the
pancreases, which interrupts the communication between islet basement membrane proteins and the integrins expressed by the islets (83). The loss of the interaction between the internal cells and the external microenvironment also interrupts the transmission of pro-survival signals (84). The isolation of pancreatic islets eventually leads to the increased expression of many stress kinases, which subsequently activates pro-inflammatory and pro-apoptotic pathways (43, 85). Furthermore, the functional clustering of differentially expressed genes revealed the upregulation of genes related to cell growth, angiogenesis, inflammation, and apoptosis after isolation and culture (43). A study has shown that islets in early culture (2 days) express more genes, including IL-1β, than islets in long-term culture (7-11 days). It seems that culturing islets before transplantation is beneficial for reducing the expression of inflammatory mediators (86). However, in cultured adult porcine islets, IL-1β mRNA was continuously detected at 1, 4, 8, and 11 days after isolation, and slightly increased over time (87). It is worth noting that a pretreatment culture with anakinra (IL-1 receptor antagonist) prior to human islet transplantation can improve the survival and function of human islets during culture (88).

The early damage of pancreatic islets is mainly manifested by an IBMIR, leading to a cytokine storm, involving IL-1β, TNF-α, and IFN-γ. These cytokine-activated macrophages produce IL-1β, which triggers the cytokine storm at the transplantation site, leading to a negative chain of events (89). Syngeneic transplant models have shown that the nonspecific inflammatory response increases IL-1β at the transplant site and affects early graft failure. In that study, the expression of IL-1β mRNA was maximal on day 1 after transplantation and then declined towards pre-transplantation levels on day 7 (90). Previous animal studies have indicated that approximately 60% of islet grafts lose their function via non-specific inflammation within 3 days after transplantation (91, 92). The overexpression of IL-1β receptor antagonist protein in transplanted islets can improve the outcome of the transplantation (93).

**TNF-α**

In humans, it appears that IL-1β must act in combination with IFN-γ and/or TNF-α (76). After TNF-α binds to the TNF receptor (TNF-R), it forms a trimer and undergoes conformational changes, which leads to the exposure of the intracellular death domain, and initiates the activation of NF-κB, the activation of the MAPK pathway, and the induction of apoptosis (40). Wen et al. revealed that TNF-α was significantly elevated in patients following allogeneic islet cell infusion compared with patients receiving autologous transplantation (94). Recently, multiple studies have shown that after pancreatic islet allotransplantation, the early use of a combination of anti-IL-1β (anakinra) and TNF-α (etanercept) inflammation blockade is beneficial for reducing islet damage caused by nonspecific inflammation and presumably led to better engraftment (95) (Figure 1).

**IFN-γ**

IFN-γ binds to the IFN-γ receptor (IFN-γR) and causes the activation of JAK1 and JAK2. JAK2 then activates signal transducers and activators of transcription 1 (STAT1), which then transfers to the nucleus, where it performs gene regulation. NO affects many physiological β-cell processes, including inhibition.
of oxidative metabolism, changes in the expression of target genes, inhibition of glucose-stimulated insulin secretion, damage to DNA, and induction of endoplasmic reticulum (ER) stress. If exposure to NO is prolonged, it activates various signal cascades and eventually leads to the death of β cells (102). In xenogeneic islet transplantation animal models, selective iNOS inhibitors can suppress the production of induced NO, to prevent early islet graft failure (103).

**IMMUNE CELLS**

**Macrophages**

Macrophages, which are one of the cellular components of the innate immune system, show great heterogeneity in physiological and pathological conditions. They can be polarized into pro-inflammatory macrophages (M1) or anti-inflammatory macrophages (M2) in different environments (104). Lipopolysaccharide and interferon IFN-γ can activate M1 macrophages to secrete TNF-α, iNOS and superoxide anion to play pro-inflammatory and host defense functions. In contrast, M2 macrophages have a protective role in the immune response and inflammation. Other studies showed that M2 macrophages can be activated by interleukin (IL)-4 and IL-13, and play an immune regulatory and anti-inflammatory role, through the secretion of IL-1Ra, IL-1, TNF-α, IL-10, and other cytokines (104, 105).

After the islets are infused into the portal vein, the activated liver-resident macrophages (Kupffer cells) play a central role in the inflammatory responses within the liver, secreting a series of factors (including arachidonic acid metabolites, TNF-α, IFN-γ, IL-1, IL-6, complement, coagulation factors, reactive oxygen species and nitrogen) to recognize and respond to various signals from the surrounding microenvironment, directly affecting the survival of intrahepatic islets (11, 106, 107). Furthermore, Kupffer cells can induce a response of other non-immune cell subsets, including endothelial cells (108). In addition, it has been suggested that ischemia reperfusion phenomena may directly trigger the activation of sinusoidal endothelial cells and help trigger nonspecific inflammatory responses (109). The transplanted islets, residual endotoxin produced in the process of islet isolation, and liver sinusoidal endothelial damage can all activate Kupffer cells (11, 110). In addition, tissue damage can recruit inflammatory macrophages (M1), which in turn cause islet damage (111). At the same time, dying β cells also produce high mobility group box 1 (HGMB) and iNOS, attracting more macrophages to the liver, and enhancing inflammation and β cell death (14, 112) (Figure 2).

Macrophage depletion can significantly reduce the expression of IL-1β and TNF-α, indicating the role of macrophages in the production of inflammatory cytokines (11). Gou et al. demonstrated that Alpha-1 antitrypsin can protect the survival of islet grafts, in part by inhibiting the polarization of M1 macrophages both in vivo and in vitro (14). One study has mentioned that the local sustained-release of dexamethasone in grafts promotes the survival of mouse pancreatic islet grafts by inducing the differentiation of M2 macrophages in the graft microenvironment as well as the secretion of anti-inflammatory factors (104). Chappell et al. showed that activated M2 macrophages could improve the survival conditions of grafts in a mouse model by improving revascularization or neovascularization, which had a repair function in the graft reaction (113).

**Lymphocytes**

Type I diabetes is characterized by the autoimmune-mediated damage of islet β-cells, and the transplanted islets will also be

---

**FIGURE 2** | Interaction between various types of cells after islet transplantation. Macrophages secreting TNF-α and iNOS, which act on beta-cells and endothelial cells to play a pro-inflammatory function; Kupffer cells secreting a series of substances (including IL-1β, IFN-γ and TNF-α), directly affecting the survival of intrahepatic islets and endothelial cells; Antigen presenting cells (APCs) take and process antigens from donor and present antigens to host T cells, then reactive CD8+, CD4+ T-cells destroy transplanted islet β cells.
attacked by the same stresses that destroy host β-cells (40). CD8+ T cells and CD4+ T cells are the major players in the destruction of β cells. Activated T cells produce cytokines such as IFN-γ, TNF-α, and lymphotxin to induce β cell apoptosis. T cells also express ligands for the Fas receptor and TNF-related apoptosis-inducing ligands, both of which lead to apoptosis by activating effector caspases. In addition, CD8+ T cells directly contact and promote the release of granzyme B into the cytoplasm of target cells through perforin, thereby activating nucleases and caspases to kill the target cells (40, 98). In some studies, CD8+ T cell infiltration was observed in the pancreas of type 1 diabetic patients and the transplanted pancreas (114, 115). In mouse models, deficiency of CD4+ T cells was observed to stop progression to insulitis (116).

During the rejection of allogeneic transplantation, the host immune response can directly or indirectly be activated by T cells recognizing the donor tissue. Direct graft recognition involves an interaction between the donor tissue resident antigen-presenting cells (APCs) and host T cells via major histocompatibility complex (MHC) (117). Indirect recognition involves the treatment of donor graft peptides by host APCs and corresponding MHC interactions to stimulate host T cells (118). APCs, including macrophages, dendritic cells (DC), passenger leukocytes, from both donors and host are involved in the antigen presentation (40). The activation and maturation of T cells depends on the signals from the above APCs. If these signals are blocked, T cells will undergo apoptosis (Figure 2).

DCs can not only initiate an immune response, but also induce central or peripheral immune tolerance (40). Mature or activated DCs can initiate a positive immune response, while immature DCs or DC precursors show tolerance. NF-κB is a transcription factor that is necessary for DC differentiation and maturation. The inhibition of the NF-κB pathway has been shown to produce tolerogenic DCs (119). RelB is a major NF-κB protein, which inhibits the expression of MHC-II, CD80, and CD86, and ultimately prevents the maturation of dendritic cells. RelB silenced DCs can inhibit antigen-specific alloreactive immune rejection and reduce the proliferation of antigen-specific T cells (120). In another study, tolerogenic DCs were generated by inhibiting the expression of CD80 or CD86. The administration of modified dendritic cells (DC) can prolong the survival of allografts, thereby inducing T cell hyporesponsiveness and apoptosis (121).

**Granulocytes**

The poor outcome of intraportal islet transplantation can be explained by IBMIR, one of which is characterized by leukocyte infiltration. The islets were mixed with ABO-compatible blood in a heparinized tube, and the first neutrophilic granulocytes appeared in the islets after 15 minutes, increasing at 1 hour and peaking at 2 hours (122). Neutrophilic granulocytes induce cell damage through cytotoxic attack and phagocytosis. After neutrophil activation, superoxide is produced to form reactive oxygen species (ROS) and release protease, both of which are involved in killing microbes (123). Neutrophilic granulocytes are also known to contain a large number of cytokines, which are released upon activation, and there is much evidence that cytokines have a damaging effect on pancreatic islets (124). And their infiltration results in the release of chemokines such as TNF-α and macrophage inflammatory protein 1α (MIP-1α) from T cells and macrophages. The mobilization of this immune effector may have effects on specific immune systems, inducing and enhancing cellular rejection (122). The massive infiltration of neutrophilic granulocytes not only causes functional impairment or reduces the mass of the implanted islets, but may also amplify the subsequent immune response, causing direct damage to the islets (125). Therefore, the development of drugs targeting neutrophil toxicity may markedly improve the outcome of intraportal islet transplantation.

**Endothelial Cells**

Pancreatic islets have an extensive capillary network, which—in addition to providing nutrients and oxygen to the islet endocrine cells and transporting hormones to the peripheral circulation—is an important source of signals for improving the survival rate and function of islet β cells (126). While islets only constitute 1% of the weight of the pancreas, they receive approximately 15% of the blood flow of the pancreas (127). In the process of the isolation, the islets are disrupted from the surrounding tissue and the capillary networks. Therefore, revascularization of the islets after transplantation is important for the function and survival of the islet graft. The endothelial cells retained in the islets after islet isolation are lost after the islets are cultured for 7 days. The isolated islets are considered to be an avascular tissue, and revascularization is carried out through the blood vessels that grow from the host organ to the islets (128). Angiogenesis begins on the first day after transplantation, and vascular remodeling may continue for up to 3 months (129). In comparison to cultured islets, transplantation of freshly isolated islets containing numerous endothelial cells may significantly improve the vascularization of transplanted islets, which in turn leads to an enhanced endocrine function and the survival of islet grafts (130). Olsson et al. observed that islet grafts obtained from freshly isolated islets have higher vascular density and oxygen tension, as well as higher ability to cure chemically induced diabetes, in comparison to islet grafts obtained from cultured islets (131).

Pancreatic islets and vascular endothelial cells secrete high levels of vascular endothelial growth factor (VEGF), which can recruit neovascularization (132). Cheng et al. used adenovirus containing cDNA from human VEGF isoforms to transfected islets and transplanted it into diabetic nude mice. It was found that the blood glucose was normal and that the revascularization of islets was improved (133). Johansson et al. demonstrated that the production of hepatocyte growth factor (HGF) *in vitro* by endothelial cells increased the proliferation of beta cells, which in turn required VEGF from beta cells (134). VEGF can also stimulate the release of interleukins and increase blood flow to ischemic tissues (135) (Figure 2). However, the supplementation of VEGF in islet grafts may have a negative impact, which recruits and amplifies inflammation, which may destroy islets (133). Previous *in vitro* and *in vivo* studies have shown that resident liver macrophages and endothelial cells can mediate...
early islet dysfunction by secreting cytokines and activating inducible iNOS (103).

CONCLUSION

Islet transplantation remains a promising treatment to improve the quality of life for many individuals with type 1 diabetes. If the restoration of normal glucose tolerance can be achieved, non-specific inflammation during transplantation can be reduced, and immune tolerance to islet tissue can be induced, it will be an ideal treatment for this disease. However, during the process of islet transplantation—including isolation, culture, and islet implantation—inflammation, ischemia, hypoxia, and immune responses will occur, resulting in the loss of the graft. The transplantation microenvironment plays an important role. Cytokine-mediated non-specific inflammation, immune cell-mediated rejection, and endothelial cells participate in post-transplant vascular remodeling, which directly and indirectly affect graft survival. Some cytokine inhibitors and siRNA targeting complement receptors have been shown to improve the viability of transplanted islets. Understanding the influence of the microenvironment on the survival of transplanted islets, as well as possible therapeutic targets is significant for the future of islet transplantation. The improvement of the microenvironment and the continuous progress of transplantation strategies will eventually improve the prognosis of transplant recipients.

AUTHOR CONTRIBUTIONS

All authors contributed to the writing and editing of the manuscript and contributed to the article and approved the submitted version.

FUNDING

This work was supported in part by Medical Science and Technology Project of Zhejiang Province (2021PY083), Program of Taizhou Science and Technology Grant (20ywbb29), Major Research Program of Taizhou Enze Medical Center Grant (19EZDZA2), Open Project Program of Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province (21SZDSYS01, 21SZDSYS09) and Key Technology Research and Development Program of Zhejiang Province (2019C03040).

REFERENCES

1. Min BH, Shin JS, Kim JM, Kang SJ, Kim HJ, Yoon IH, et al. Delayed Revascularization of Islets After Transplantation by IL-6 Blockade in Pig to Non-Human Primate Islet Xenotransplantation Model. Xenotransplantation (2018) 25. doi: 10.1111/xen.12574
2. Shapiro A, Ricordi C, Hering B, Aucührnsoh H, Lindblad R, Robertson R, et al. International Trial of the Edmonton Protocol for Islet Transplantation. N Engl J Med (2006) 355:1318–30. doi: 10.1056/NEJMoA061267
3. Shapiro A, Lakey J, Ryan E, Korbult G, Toth E, Warnock G, et al. Islet Transplantation in Seven Patients With Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen. N Engl J Med (2000) 343:230–8. doi: 10.1056/NEJM200007273430401
4. Yang Z, Li X, Zhang C, Sun N, Guo T, Lin J, et al. Amniotic Membrane Extract Protects Islets From Serum-Deprivation Induced Impairments and Improves Islet Transplantation Outcome. Front Endocrinol (Lausanne) (2020) 11:587450. doi: 10.3389/fendo.2020.587450
5. London NJ, Robertson DR, Chadwick PR, Johnson RF, James PR, Bell PR. Human Pancreatic Islet Isolation and Transplantation. Clin Transplant (1994) 85:421–59. doi: 10.1097/00002284-199409000-00005-9
6. Brandhorst D, Brandhorst H, Layland S, Acreman S, Schenke-Layland K, Johnson PRV. Basement Membrane Proteins Protects Human Islet Survival in Hypoxia: Implications for Islet Inflammation. Acta Biomater (2021) 137:92–102. doi: 10.1016/j.actbio.2021.10.013
7. Ryan E, Paty B, Senior P, Bigam D, Alfañadhi E, Kneteman N, et al. Five-Year Follow-Up After Clinical Islet Transplantation. Diabetes (2005) 54:2060–9. doi: 10.2337/diabetes.54.7.2060
8. Noguchi H. Regulation of C-Jun NH-Terminal Kinase for Islet Transplantation. J Clin Med (2019) 8:1763. doi: 10.3390/jcm811763
9. Cavayab F, Nih LR, Yoshibara E, 732431. Advances in Pancreatic Islet Transplantation Sites for the Treatment of Diabetes. Front Endocrinol (Lausanne) (2021) 12:732431. doi: 10.3389/fendo.2021.732431
10. Citro A, Cantarelli E, Piemonti L. Anti-Inflammatory Strategies to Enhance Islet Engraftment and Survival. Curr Diab Rep (2013) 13:73–44. doi: 10.1007/s11892-013-0401-0
11. Bottino R, Fernandez L, Ricordi C, Lehmann R, Tsan M, Oliver R, et al. Transplantation of Allogeneic Islets of Langerhans in the Rat Liver: Effects of Macrophage Depletion on Graft Survival and Microenvironment Activation. Diabetes (1998) 47:316–23. doi: 10.2337/diabetes.47.3.316
12. Song HJ, Xue WJ, Li Y, Tian XF, Ding XM, Feng XS, et al. Prolongation of Islet Graft Survival Using Concomitant Transplantation of Islets and Vascular Endothelial Cells in Diabetic Rats. Transplant Proc (2010) 42:2662–5. doi: 10.1016/j.transproceed.2010.06.003
13. Szempruch K, Banerjee O, McCall R, Desai CJ. Use of Anti-Inflammatory Agents in Clinical Islet Cell Transplants: A Qualitative Systematic Analysis. Islets (2019) 11:65–75. doi: 10.1080/19382101.2019.1601543
14. Gou W, Wang J, Song L, Kim DS, Cui W, Strange C, et al. Alpha-1 Antitrypsin Suppresses Macrophage Activation and Promotes Islet Graft Survival After Intrahepatic Islet Transplantation. Am J Transplant (2021) 21:1713–24. doi: 10.1111/ajt.16342
15. Scharp D, Lacy P, Santiago J, McCullough C, Weide L, Falqui L, et al. Insulin Independence After Islet Transplantation Into Type 1 Diabetic Patient. Diabetes (1990) 39:515–8. doi: 10.2337/diabetes.39.4.515
16. Bottino R, Knoll MF, Knoll CA, Bertera S, Trucco MM. The Future of Islet Transplantation Is Now. Front Med (Lausanne) (2018) 5:202. doi: 10.3389/fmed.2018.00202
17. Hering B, Clarke W, Bridges N, Eggertman T, Alejandro R, Bellin M, et al. Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care (2016) 39:1230–40. doi: 10.2337/dc15-1988
18. Lablanche S, Vantyghem M, Kessler L, Wojtusciszyn A, Borot S, Thivolet C, et al. Islet Transplantation Versus Insulin Therapy in Patients With Type 1 Diabetes With Severe Hypoglycaemia or Poorly Controlled Glycaemia After Kidney Transplantation (TRIMECO): A Multicentre, Randomised Controlled Trial. Lancet Diabetes Endocrinol (2018) 6:527–37. doi: 10.1016/S2213-8587(18)30078-0
19. Infante M, Ricordi C, Padilla N, Alvarez A, Linetsky E, Lanzoni G, et al. The Role of Vitamin D and Omega-3 PUFA s in Islet Transplantation. Nutrients (2019) 11:2937. doi: 10.3390/nu11122937
20. Yamane K, Anazawa T, Tada S, Fujimoto N, Inoguchi K, Emoto N, et al. AndMitomycin C Treatment Improves Pancreatic Islet Graft Longevity in Intraportal Islet Transplantation by Suppressing Proinflammatory Response. Sci Rep (2020) 10:12086. doi: 10.1038/s41598-020-69009-8
21. Rickels MR, Robertson RP. Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions. *Endocr Rev* (2019) 40:631–68. doi: 10.1210/er.2018-00154

22. Razavi M, Zheng F, Telchico A, Wang J, Ren G, Dahl J, et al. Improving the Function and Engraftment of Transplanted Pancreatic Islets Using Pulsed Focused Ultrasound Therapy. *Sci Rep* (2019) 9. doi: 10.1038/s41598-019-49933-0

23. Bennet W, Groth C, Larsson N, Nilsson B, Korsgren O. Isolated Human Islets Trigger an Instant Blood Mediated Inflammatory Reaction: Implications for Intraportal Islet Transplantation as a Treatment for Patients With Type 1 Diabetes. *Ups J Med Sci* (2000) 105:125–33. doi: 10.1517/030097340000000059

24. Nilsson B, Ekdahl K, Korsgren O. Control of Instant Blood-Mediated Inflammatory Reaction to Improve Islets of Langerhans Engraftment. *Curr Opin Organ Transplant* (2011) 16:620–6. doi: 10.1097/MOT.0b013e32834c2393

25. Goto M, Johansson H, Maeda A, Elgue G, Korsgren O, Nilsson BJT. Low Molecular Weight Dextran Sulfate Prevents the Instant Blood-Mediated Inflammatory Reaction Induced by Adult Porcine Islets. *Transplantation* (2004) 77:741–7. doi: 10.1097/01.TP.0000114872.26990.4F

26. von Zur-Mühlen B, Lundgren T, Bayman L, Berne C, Bridges N, Eggerman A, et al. Pancreatic Islet Transplantation: Toward Definitive Treatment for Diabetes Mellitus. *Glob Health Med* (2020) 2:200–11. doi: 10.35772/ghm.2020.01057

27. Cabric S, Sanchez J, Lundgren T, Foss A, Feldlin M, Kallen R, et al. Islet Surface Heparinization Prevents the Instant Blood-Mediated Inflammatory Reaction in Inlet Transplantation. *Diabetes* (2007) 56:2008–15. doi: 10.2337/db07-0358

28. Contreras J, Eckstein C, Smyth C, Bilbao G, Vilatoba M, Ringland S, et al. Open Randomized Multicenter Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran in Inlet Transplantation. *Transplantation* (2008) 85:630–7. doi: 10.1097/TP.0b013e31815d2a25

29. Takaki T, Shimoda M. And Medicine, Pancreatic Islet Transplantation: Against With the Twelve Years. *J Exp Med* (2013) 220:1619–20. doi: 10.1084/jem.2012.12.337

30. Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P, et al. Insulin-Heparin Infusions Peritransplant Substantially Improve Single-Donor Clinical Islet Transplant Success. *Transplantation* (2010) 89:465–71. doi: 10.1097/TP.0b013e3181c47f8d

31. Johansson H, Goto M, Dufrane D, Siegbahn A, Elgue G, Gianello P, et al. Low Molecular Weight Dextran Sulfate: A Strong Candidate Drug to Block IMMORTALIZED Islet Mass After Intraportal Transplantation: A Novel Link Between Endothelial Cell Activation, Thrombosis, Inflammation, and Islet Cell Death. *Diabetes* (2004) 53:2804–14. doi: 10.2337/diabetes.53.11.2804

32. Peng Q, Li K, Patel H, Sacks S, Zhou W. Dendritic Cell Synthesis of C3 Is Required for Full T Cell Activation and Development of a Th1 Phenotype. *J Immunol* (2002) 8:582–7. doi: 10.1089/jimmunol.2002.6062-5081

33. Brown K, Kondeatis E, Vaughan R, Kon S, Farmer C, Taylor J, et al. Influence of Donor C3 Allotype on Late Renal-Transplantation Outcome. *N Engl J Med* (2006) 354:2014–23. doi: 10.1056/NEJMoa052825

34. Barrault D, Steward M, Cox V, Smith R, Knight A. Efficient Production of Complex (CSD)3 Fusion Proteins Using the Baculovirus Expression Vector System. *J Immunol Methods* (2005) 304:158–73. doi: 10.1016/j.jim.2005.07.013

35. Li F, Mahato RI. RNA Interference for Improving the Outcome of Islet Transplantation. *Adv Drug Deliv Rev* (2011) 63:67–68. doi: 10.1016/j.addr.2010.11.003

36. Peng Q, Li K, Patel H, Sacks S, Zhou W. Dendritic Cell Synthesis of C3 Is Required for Full T Cell Activation and Development of a Th1 Phenotype. *J Immunol* (2002) 8:582–7. doi: 10.1089/jimmunol.2002.6062-5081

37. Pratt J, Basheer S, Sacks S. Local Synthesis of Component Complex Component C3 Regulates Acute Renal Transplant Rejection. *Nat Med* (2002) 8:582–7. doi: 10.1038/960002a

38. Brown K, Kondeatis E, Vaughan R, Kon S, Farmer C, Taylor J, et al. Influence of Donor C3 Allotype on Late Renal-Transplantation Outcome. *N Engl J Med* (2006) 354:2014–23. doi: 10.1056/NEJMoa052825
Yan et al. Microenvironment of Transplanted Islets

60. Vallabhajosyula P, Hirakata A, Shimizu A, Okumi M, Tchipashvili V, Hong
59. Pathak S, Regmi S, Gupta B, Pham T, Yong C, Kim J, et al. Engineered Islet
58. Pileggi A, Molano R, Ricordi C, Zahr E, Collins J, Valdes R, et al. Reversal of
57. Lee SJ, Kim HJ, Byun NR, Park CG. Donor-Specific
56. Domhan S, Zeier M, Abdollahi AJN. Dialysis, Transplantation: Of
55. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
54. Britt L, Scharp D, Lacy P, Slavin SJD. Transplantation of Islet Cells Across
53. Mizrahi N, Braun M, Ben Gal T, Rosengarten D, Kramer M, Grossman AJE.
52. doi: 10.2337/diabetes.50.7.1546
51. Kanak MA, Takita M, Kunnathodi F, Lawrence MC, Levy MF, Naziruddin B.
50. doi: 10.1111/ajt.13975
49. Cross SE, Vaughan RH, Wilcox AJ, McBride AJ, Abraham AA, Han B, et al.
48. Nano E, Petropavlovskaia M, Rosenberg L. Islet Neogenesis Associated
47. Cross SE, Vaughan RH, Willcox AJ, McBride AJ, Abraham AA, Han B, et al.
46. Lee SJ, Kim HJ, Byun NR, Park CG. Donor-Specific Regulatory T Cell-
45. Lee SJ, Kim HJ, Byun NR, Park CG. Donor-Specific Regulatory T Cell-
44. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
43. Mizrahi N, Braun M, Ben Gal T, Rosengarten D, Kramer M, Grossman AJE.
42. Domhan S, Zeier M, Abdollahi AJN. Dialysis, Transplantation: Of
41. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
40. Britt L, Scharp D, Lacy P, Slavin SJD. Transplantation of Islet Cells Across
39. Cross SE, Vaughan RH, Wilcox AJ, McBride AJ, Abraham AA, Han B, et al.
38. Domhan S, Zeier M, Abdollahi AJN. Dialysis, Transplantation: Official
37. Lee SJ, Kim HJ, Byun NR, Park CG. Donor-Specific Regulatory T Cell-
36. Lee SJ, Kim HJ, Byun NR, Park CG. Donor-Specific Regulatory T Cell-
35. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
34. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
33. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
32. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
31. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
30. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
29. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
28. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
27. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
26. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
25. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
24. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
23. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
22. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
21. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
20. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
19. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
18. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
17. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
16. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
15. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
14. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
13. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
12. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
11. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
10. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
9. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
8. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
7. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
6. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
5. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
4. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
3. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
2. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
1. van Doesum W, Gard L, Bemelman F, de Fijter J, Homan van der Heide J,
104. Li Y, Ding X, Tian X, Zheng J, Ding C, Li X, et al. Islet Transplantation

103. Brandhorst D, Brandhorst H, Zwolinski A, Nahidi F, Bretzel RJT. Prevention

102. Oleson BJ, Corbett JA. Dual Role of Nitric Oxide in Regulating the Response

101. Li B, Liu Y, Cheng Y, Zhang K, Li T, Zhao N. Protective Effect of Inducible

Frontiers in Immunology | www.frontiersin.org March 2022 | Volume 13 | Article 849580

105. Gordon S, Plüddemann A, Martinez Estrada F. Macrophage Heterogeneity

97. Ozasa T, Newton M, Dallman M, Shimizu S, Gray D, Morris PJT. Cytokine

98. Eizirik D, Mandrup-Poulsen TJD. A Choice of Death

99. Saldeen J. Cytokines Induce Both Necrosis and Apoptosis

96. Tau G, Rothman PJA. Biologic Functions of the IFN-Gamma Receptors.

94. Chung WY, Pollard CA, Kumar R, Drogemuller CJ, Naziruddin B, Stover C,

113. Chappell A, Lujan-Hernandez J, Perry D, Corvera S, Lalikos JJP. Alternatively Activated M2 Macrophages Improve Autologous Fat Graft Survival in a Mouse Model Through Induction of Angiogenesis. P las Reconstr Surg (2015) 136:277e. doi: 10.1097/PRS.0000000000001435

112. Wang J, Gou W, Kim D, Strange C, Wang HJT. Clathrin-Mediated Endocytosis of Alpha-1 Antitrypsin Is Essential for Its Protective Function in Islet Cell Survival. Theranostics (2019) 9:3940–51. doi: 10.7150/thno.31647

111. de Groot M, Schuurs T, Keizer P, Fekken S, Leuvenink H, Van Schilfgaarde R. Response of Encapsulated Rat Pancreatic Islets to Hypoxia. Cell Transplant (2003) 12:867–75. doi: 10.3727/000000000003

771000219

110. Wang J, Gou W, Kim D, Strange C, Wang HJT. Clathrin-Mediated Endocytosis of Alpha-1 Antitrypsin Is Essential for Its Protective Function in Islet Cell Survival. Theranostics (2019) 9:3940–51. doi: 10.7150/thno.31647

111. de Groot M, Schuurs T, Keizer P, Fekken S, Leuvenink H, Van Schilfgaarde R. Response of Encapsulated Rat Pancreatic Islets to Hypoxia. Cell Transplant (2003) 12:867–75. doi: 10.3727/000000000003

771000219

110. Wang J, Gou W, Kim D, Strange C, Wang HJT. Clathrin-Mediated Endocytosis of Alpha-1 Antitrypsin Is Essential for Its Protective Function in Islet Cell Survival. Theranostics (2019) 9:3940–51. doi: 10.7150/thno.31647

111. de Groot M, Schuurs T, Keizer P, Fekken S, Leuvenink H, Van Schilfgaarde R. Response of Encapsulated Rat Pancreatic Islets to Hypoxia. Cell Transplant (2003) 12:867–75. doi: 10.3727/000000000003

771000219

110. Wang J, Gou W, Kim D, Strange C, Wang HJT. Clathrin-Mediated Endocytosis of Alpha-1 Antitrypsin Is Essential for Its Protective Function in Islet Cell Survival. Theranostics (2019) 9:3940–51. doi: 10.7150/thno.31647

111. de Groot M, Schuurs T, Keizer P, Fekken S, Leuvenink H, Van Schilfgaarde R. Response of Encapsulated Rat Pancreatic Islets to Hypoxia. Cell Transplant (2003) 12:867–75. doi: 10.3727/000000000003

771000219

110. Wang J, Gou W, Kim D, Strange C, Wang HJT. Clathrin-Mediated Endocytosis of Alpha-1 Antitrypsin Is Essential for Its Protective Function in Islet Cell Survival. Theranostics (2019) 9:3940–51. doi: 10.7150/thno.31647

111. de Groot M, Schuurs T, Keizer P, Fekken S, Leuvenink H, Van Schilfgaarde R. Response of Encapsulated Rat Pancreatic Islets to Hypoxia. Cell Transplant (2003) 12:867–75. doi: 10.3727/000000000003

771000219

110. Wang J, Gou W, Kim D, Strange C, Wang HJT. Clathrin-Mediated Endocytosis of Alpha-1 Antitrypsin Is Essential for Its Protective Function in Islet Cell Survival. Theranostics (2019) 9:3940–51. doi: 10.7150/thno.31647

111. de Groot M, Schuurs T, Keizer P, Fekken S, Leuvenink H, Van Schilfgaarde R. Response of Encapsulated Rat Pancreatic Islets to Hypoxia. Cell Transplant (2003) 12:867–75. doi: 10.3727/000000000003

771000219

110. Wang J, Gou W, Kim D, Strange C, Wang HJT. Clathrin-Mediated Endocytosis of Alpha-1 Antitrypsin Is Essential for Its Protective Function in Islet Cell Survival. Theranostics (2019) 9:3940–51. doi: 10.7150/thno.31647

111. de Groot M, Schuurs T, Keizer P, Fekken S, Leuvenink H, Van Schilfgaarde R. Response of Encapsulated Rat Pancreatic Islets to Hypoxia. Cell Transplant (2003) 12:867–75. doi: 10.3727/000000000003

771000219
131. Olsson R, Carlsson PJD. Better Vascular Engraftment and Function in Pancreatic Islets Transplanted Without Prior Culture. *Diabetologia* (2005) 48:469–76. doi: 10.1007/s00125-004-1650-x

132. Figliuzzi M, Bonandrini B, Silvani S, Remuzzi A. Mesenchymal Stem Cells Help Pancreatic Islet Transplantation to Control Type 1 Diabetes. *World J Stem Cells* (2014) 6:163–72. doi: 10.4252/wjsc.v6.i2.163

133. Cheng K, Fraga D, Zhang C, Kotb M, Gaber A, Guntaka R, et al. Adenovirus-Based Vascular Endothelial Growth Factor Gene Delivery to Human Pancreatic Islets. *Gene Ther* (2004) 11:1105–16. doi: 10.1038/sj.gt.3302267

134. Johansson M, Mattsson G, Andersson A, Jansson L, Carlsson PO. Islet Endothelial Cells and Pancreatic Beta-Cell Proliferation: Studies In Vitro and During Pregnancy in Adult Rats. *Endocrinology* (2006) 147:2315–24. doi: 10.1210/en.2005-0997

135. Gamble A, Pepper AR, Bruni A, Shapiro AMJ. The Journey of Islet Cell Transplantation and Future Development. *Islets* (2018) 10:80–94. doi: 10.1080/19382014.2018.1428511

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yan, Ye, Chen, He, Zhang, Mao and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.